The Karolinska Institutet’s Academic Specialist Center (ASC) to Present Results of GeNeuro’s ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022
25 Oktober 2022 - 7:30AM
Business Wire
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a
biopharmaceutical company focused on stopping causal factors
driving the progression of neurodegenerative and autoimmune
diseases such as multiple sclerosis (MS), amyotrophic lateral
sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC,
long-COVID or post-COVID), announced it will present Phase IIb
safety and efficacy data on temelimab from its ProTEct-MS study at
the 38th Congress of the European Committee for Treatment and
Research in Multiple Sclerosis in Amsterdam, Netherlands.
The trial was conducted at the Karolinska Institutet’s Academic
Specialist Center in Stockholm, Sweden. The one-year Phase 2 trial
evaluated the administration of temelimab in patients with
relapsing remitting MS to address disease progression independent
of relapses following treatment with rituximab.
As a reminder, the topline results of the Phase 2 ProTEct-MS
study, communicated in March 2022, confirmed the excellent safety
profile and tolerability of higher doses of temelimab and the
synergistic potential to treat neurodegeneration in addition to
anti-inflammatory therapy in multiple sclerosis. Efficacy data,
obtained in patients already treated effectively for inflammation,
showed that temelimab has a favorable impact on key MRI parameters
measuring neurodegeneration.
The presentation, entitled “Primary analysis of ProTEct-MS, a
randomized, placebo-controlled, phase 2 study of Temelimab for the
prevention of neurodegeneration in rituximab-treated patients with
relapsing multiple sclerosis,” will be made by Prof. Fredrik Piehl,
Principal Investigator of the study, during the “Free
Communications 5: Treatment” session on Thursday, October 27, 2022,
at 3:30 pm CEST.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by human
endogenous retroviruses (HERVs), which represent 8% of human
DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer:
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words, such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221024005875/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap (France) Mathilde Bohin/ Louis-Victor Delouvrier
(investors) +33 1 44 71 98 52
Arthur Rouillé (media) +33 1 44 71 94 98 geneuro@newcap.eu
RooneyPartners (US) Jeanene Timberlake (media) +1 646 770
8858 jtimberlake@rooneypartners.com
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024